Loading...
Market
What will be the outcome of Johnson & Johnson's acquisition attempt of Intra-Cellular Therapies by end of 2025?
3
Resolution / Starting Odds
Acquisition Completed • 25%
Acquisition Abandoned • 25%
Acquisition Delayed • 25%
Other Outcomes • 25%
Official press releases from Johnson & Johnson or Intra-Cellular Therapies, major financial news outlets
Story
Johnson & Johnson Explores $14.6 Billion Acquisition of Intra-Cellular Therapies at JPM25
Jan 13, 2025, 12:57 PM
Johnson & Johnson is exploring a potential acquisition of Intra-Cellular Therapies, a biopharmaceutical company co-founded in 2002 by Sharon Mates based on Nobel laureate Paul Greengard's research, in what could be one of the largest biotech deals in recent years valued at $14.6 billion. The discussions are ongoing, and no deal is certain, but the move could see Johnson & Johnson expand its portfolio in the biopharma sector. Intra-Cellular Therapies, with a market value of approximately $10 billion, is known for its drug Caplyta, which was first FDA-approved in December 2019. The acquisition, if completed, would mark a significant move in the healthcare industry, which has seen increased merger and acquisition activity. CEO Sharon Mates and the board have agreed to sell the company at the JPM25 conference.
View original story
Similar markets
Acquisition abandoned • 25%
Acquisition delayed • 25%
No official outcome by end of 2025 • 25%
Acquisition completed • 25%
No • 50%
Yes • 50%
Yes • 50%
No • 50%
Increase by more than 10% • 25%
Decrease • 25%
No significant change • 25%
Increase by 5-10% • 25%
No • 50%
Yes • 50%
Increase by 0-10% • 25%
Decrease • 25%
No change • 25%
Increase by more than 10% • 25%
No • 50%
Yes • 50%
More than $14 billion • 25%
No acquisition announced • 25%
$12 billion to $14 billion • 25%
Less than $12 billion • 25%